Q&A: FDA Panel Member Tells Healthline Why He Resigned Over Alzheimer’s Drug Approval
Similar Posts
Mom of Child with Special Needs: “My Greatest Fear is a Cut to Medicaid”
AOTA champions funding for children with disabilities who receive occupational therapy services in schools Washington, DC — As an…
AllyGPO Appoints Dustin Faircloth President of AllyOncology
Experienced oncology executive to lead expanding business as AllyOncology AllyGPO®, a leading innovator and next-generation specialty group purchasing organization (GPO), today…
Researchers from the GIST Propose Ultrasound Stimulation as an Effective Therapy for Alzheimer’s Disease in New Study
Synchronizing one’s brainwaves to ultrasound pulses could reduce the accumulation of abnormal proteins characteristic of the onset of Alzheimer’s…
ACOs and Chronic Care Management: What Cloud-based Comms Can Do for You
by Perry Price, CEO, Revation Systems As a large percentage of the baby boomer population transitions into Medicare, terms like “accountable…
Cricket Health Appoints Dr. Carmen A. Peralta as Chief Medical Officer
Commitment to Patients at Heart of Multidisciplinary Care Program for Those with Kidney Disease Cricket Health, a specialty care provider…
